684 related articles for article (PubMed ID: 15639212)
1. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis.
Rothberg MB; Rose DN
Am J Med; 2005 Jan; 118(1):68-77. PubMed ID: 15639212
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of influenza vaccination in working-age cancer patients.
Avritscher EB; Cooksley CD; Geraci JM; Bekele BN; Cantor SB; Rolston KV; Elting LS
Cancer; 2007 Jun; 109(11):2357-64. PubMed ID: 17457827
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of vaccination versus treatment of influenza in healthy adolescents and adults.
Muennig PA; Khan K
Clin Infect Dis; 2001 Dec; 33(11):1879-85. PubMed ID: 11692300
[TBL] [Abstract][Full Text] [Related]
4. Management of influenza symptoms in healthy children: cost-effectiveness of rapid testing and antiviral therapy.
Rothberg MB; Fisher D; Kelly B; Rose DN
Arch Pediatr Adolesc Med; 2005 Nov; 159(11):1055-62. PubMed ID: 16275797
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States.
Luce BR; Nichol KL; Belshe RB; Frick KD; Li SX; Boscoe A; Rousculp MD; Mahadevia PJ
Vaccine; 2008 Jun; 26(23):2841-8. PubMed ID: 18462851
[TBL] [Abstract][Full Text] [Related]
6. Pertussis in adolescents and adults: should we vaccinate?
Lee GM; Lebaron C; Murphy TV; Lett S; Schauer S; Lieu TA
Pediatrics; 2005 Jun; 115(6):1675-84. PubMed ID: 15930232
[TBL] [Abstract][Full Text] [Related]
7. Could a federal program to promote influenza vaccination among elders be cost-effective?
Patel MS; Davis MM
Prev Med; 2006 Mar; 42(3):240-6. PubMed ID: 16480761
[TBL] [Abstract][Full Text] [Related]
8. Influence of clinical case definitions with differing levels of sensitivity and specificity on estimates of the relative and absolute health benefits of influenza vaccination among healthy working adults and implications for economic analyses.
Nichol KL; Mendelman P
Virus Res; 2004 Jul; 103(1-2):3-8. PubMed ID: 15163481
[TBL] [Abstract][Full Text] [Related]
9. Oseltamivir for influenza postexposure prophylaxis: economic evaluation for children aged 1-12 years in the U.S.
Talbird SE; Brogan AJ; Winiarski AP
Am J Prev Med; 2009 Nov; 37(5):381-8. PubMed ID: 19840692
[TBL] [Abstract][Full Text] [Related]
10. Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older.
Maciosek MV; Solberg LI; Coffield AB; Edwards NM; Goodman MJ
Am J Prev Med; 2006 Jul; 31(1):72-9. PubMed ID: 16777545
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of a recommendation of universal mass vaccination for seasonal influenza in the United States.
Clements KM; Chancellor J; Nichol K; DeLong K; Thompson D
Value Health; 2011; 14(6):800-11. PubMed ID: 21914499
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of universal influenza vaccination in a pregnant population.
Roberts S; Hollier LM; Sheffield J; Laibl V; Wendel GD
Obstet Gynecol; 2006 Jun; 107(6):1323-9. PubMed ID: 16738159
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of influenza and pneumococcal vaccination for Hong Kong elderly in long-term care facilities.
You JH; Wong WC; Ip M; Lee NL; Ho SC
J Epidemiol Community Health; 2009 Nov; 63(11):906-11. PubMed ID: 19608558
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.
Manser R; Dalton A; Carter R; Byrnes G; Elwood M; Campbell DA
Lung Cancer; 2005 May; 48(2):171-85. PubMed ID: 15829317
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.
Shepard CW; Ortega-Sanchez IR; Scott RD; Rosenstein NE;
Pediatrics; 2005 May; 115(5):1220-32. PubMed ID: 15867028
[TBL] [Abstract][Full Text] [Related]
16. The cost effectiveness of influenza vaccination for adults aged 50 to 64 years: a model-based analysis for Spain.
Aballéa S; De Juanes JR; Barbieri M; Martin M; Chancellor J; Oyagüez I; Verwee B; Largeron N
Vaccine; 2007 Sep; 25(39-40):6900-10. PubMed ID: 17764790
[TBL] [Abstract][Full Text] [Related]
17. The effectiveness of vaccination against influenza in healthy, working adults.
Nichol KL; Lind A; Margolis KL; Murdoch M; McFadden R; Hauge M; Magnan S; Drake M
N Engl J Med; 1995 Oct; 333(14):889-93. PubMed ID: 7666874
[TBL] [Abstract][Full Text] [Related]
18. Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin.
Shorr AF; Susla GM; Kollef MH
Crit Care Med; 2004 Jan; 32(1):137-43. PubMed ID: 14707572
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of botulinum toxin a versus anticholinergic medications for idiopathic urge incontinence.
Wu JM; Siddiqui NY; Amundsen CL; Myers ER; Havrilesky LJ; Visco AG
J Urol; 2009 May; 181(5):2181-6. PubMed ID: 19296983
[TBL] [Abstract][Full Text] [Related]
20. The cost-effectiveness of a universal influenza vaccination program for adults aged 50-64 years in Australia.
Newall AT; Scuffham PA; Kelly H; Harsley S; Macintyre CR
Vaccine; 2008 Apr; 26(17):2142-53. PubMed ID: 18343537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
